JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB74095

Anti-NCF1/p47-phox (phospho S359) 抗体

Anti-NCF1/p47-phox (phospho S359) antibody

Be the first to review this product! Submit a review

|

(2 Publications)

Rabbit Polyclonal NCF1/p47-phox phospho S359 antibody. Suitable for WB, IHC-P, ICC/IF and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Synthetic Peptide within Human NCF1 pS359.

別名を表示する

NOXO2, SH3PXD1A, NCF1, Neutrophil cytosol factor 1, NCF-1, 47 kDa autosomal chronic granulomatous disease protein, 47 kDa neutrophil oxidase factor, NCF-47K, Neutrophil NADPH oxidase factor 1, Nox organizer 2, Nox-organizing protein 2, SH3 and PX domain-containing protein 1A, p47-phox

3 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NCF1/p47-phox (phospho S359) antibody (AB74095)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NCF1/p47-phox (phospho S359) antibody (AB74095)

ab74095 at 1/50 dilution staining NCF1/p47-phox in human colon carcinoma by Immunohistochemistry, Paraffin-embedded tissue, in the absence or presence of the immunising peptide.

Immunocytochemistry/ Immunofluorescence - Anti-NCF1/p47-phox (phospho S359) antibody (AB74095)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-NCF1/p47-phox (phospho S359) antibody (AB74095)

ab74095 at 1/500 dilution staining NCF1/p47-phox in HeLa cells by Immunofluorescence, in the absence or presence of the immunising peptide.

Western blot - Anti-NCF1/p47-phox (phospho S359) antibody (AB74095)
  • WB

Unknown

Western blot - Anti-NCF1/p47-phox (phospho S359) antibody (AB74095)

All lanes:

Western blot - Anti-NCF1/p47-phox (phospho S359) antibody (ab74095) at 1/500 dilution

Lane 1:

HeLa cell extracts treatedwith nocodazole (1ug/ml, 18hours) at 30 µg

Lane 2:

HeLa cell extracts treatedwith TSA (400nM, 24hours) at 30 µg

Lane 3:

HeLa cell extracts treatedwith nocodazole (1ug/ml, 18hours) and with TSA (400nM, 24hours) at 30 µg with the immunising peptide

Predicted band size: 44 kDa

Observed band size: 45 kDa

false

Key facts

宿主種

Rabbit

クローン性

Polyclonal

アイソタイプ

IgG

キャリアフリー

No

交差種

Human

アプリケーション

IHC-P, ICC/IF, WB

applications

免疫原

Synthetic Peptide within Human NCF1 pS359. The exact immunogen used to generate this antibody is proprietary information.

P14598

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/1000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/50 - 1/100", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/500 - 1/1000", "ICCIF-species-notes": "<p></p>" } } }

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Immunogen
精製に関する特記事項
ab74095 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
バッファー組成
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride
出荷温度
Blue Ice
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

NCF1 also known as p47-phox p47-phox protein or NCF-1 is a cytosolic component of the NADPH oxidase complex. It has a molecular mass of about 47 kDa. NCF1/p47-phox is expressed in neutrophils monocytes and other phagocytic cells. Functionally it plays an important role in the regulation of reactive oxygen species (ROS) production by facilitating the translocation of other subunits to the cell membrane where the NADPH oxidase complex assembles and becomes active.
Biological function summary

The NCF1/p47-phox protein plays a critical role in host defense by generating ROS which are essential for microbial killing. NCF1 is an integral part of the NADPH oxidase complex along with other subunits such as p67-phox p40-phox gp91-phox and p22-phox. When stimulated NCF1 interacts with these subunits to form an active enzyme complex that transfers electrons from NADPH to oxygen producing superoxide anion and other ROS.

Pathways

The NCF1/p47-phox component participates mainly in the NADPH oxidase activation pathway and the respiratory burst pathway. NCF1 is connected to the RAC2 GTPase which upon activation stimulates the assembly and activation of the NADPH oxidase complex at the plasma membrane. This pathway is key for the innate immune response and effective clearance of pathogens by phagocytic cells.

Mutations or dysfunction in the NCF1/p47-phox gene can lead to chronic granulomatous disease (CGD) which is characterized by a failure to produce ROS and a consequent inability to kill certain bacteria and fungi. Additionally NCF1 has links to autoimmune conditions such as rheumatoid arthritis where impaired ROS production may contribute to pathogenesis. These disease implications also involve other components of the NADPH oxidase complex such as gp91-phox whose dysfunction similarly contributes to these disorders.

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

Subunit of the phagocyte NADPH oxidase complex that mediates the transfer of electrons from cytosolic NADPH to O2 to produce the superoxide anion (O2(-)) (PubMed : 2547247, PubMed : 2550933, PubMed : 38355798). In the activated complex, electrons are first transferred from NADPH to flavin adenine dinucleotide (FAD) and subsequently transferred via two heme molecules to molecular oxygen, producing superoxide through an outer-sphere reaction (PubMed : 38355798). Activation of the NADPH oxidase complex is initiated by the assembly of cytosolic subunits of the NADPH oxidase complex with the core NADPH oxidase complex to form a complex at the plasma membrane or phagosomal membrane (PubMed : 38355798). This activation process is initiated by phosphorylation dependent binding of the cytosolic NCF1/p47-phox subunit to the C-terminus of CYBA/p22-phox (PubMed : 12732142, PubMed : 19801500).
See full target information NCF1 pS359

文献 (2)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in veterinary science 7:570593 PubMed33240950

2020

Effects of Probiotics BaSC06 on Intestinal Digestion and Absorption, Antioxidant Capacity, Microbiota Composition, and Macrophage Polarization in Pigs for Fattening.

Applications

Unspecified application

Species

Unspecified reactive species

Xuefang Cao,Li Tang,Zihan Zeng,Baikui Wang,Yuanhao Zhou,Qi Wang,Peng Zou,Weifen Li

Brain : a journal of neurology 135:886-99 PubMed22366799

2012

NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury.

Applications

IHC-P

Species

Human

Marie T Fischer,Rakhi Sharma,Jamie L Lim,Lukas Haider,Josa M Frischer,Joost Drexhage,Don Mahad,Monika Bradl,Jack van Horssen,Hans Lassmann
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com